Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Fell Below 20 DMA | Bearish | 0.29% | |
Wide Bands | Range Expansion | 0.29% | |
20 DMA Support | Bullish | -1.44% | |
Wide Bands | Range Expansion | -1.44% | |
Crossed Above 20 DMA | Bullish | -5.00% | |
Pocket Pivot | Bullish Swing Setup | -5.00% | |
Wide Bands | Range Expansion | -5.00% |
Alert | Time |
---|---|
Possible Pocket Pivot | about 11 hours ago |
Up 3% | about 12 hours ago |
Up 2% | about 12 hours ago |
Up 1% | about 12 hours ago |
60 Minute Opening Range Breakout | about 13 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/22/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Her2/Neu Cancer Center
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.44 |
52 Week Low | 7.58 |
Average Volume | 45,795 |
200-Day Moving Average | 11.23 |
50-Day Moving Average | 15.55 |
20-Day Moving Average | 13.54 |
10-Day Moving Average | 13.40 |
Average True Range | 1.19 |
RSI (14) | 45.95 |
ADX | 25.93 |
+DI | 15.70 |
-DI | 21.24 |
Chandelier Exit (Long, 3 ATRs) | 13.78 |
Chandelier Exit (Short, 3 ATRs) | 14.95 |
Upper Bollinger Bands | 15.63 |
Lower Bollinger Band | 11.46 |
Percent B (%b) | 0.53 |
BandWidth | 30.74 |
MACD Line | -0.53 |
MACD Signal Line | -0.68 |
MACD Histogram | 0.1549 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 15.17 | ||||
Resistance 3 (R3) | 15.19 | 14.71 | 14.92 | ||
Resistance 2 (R2) | 14.71 | 14.33 | 14.70 | 14.84 | |
Resistance 1 (R1) | 14.19 | 14.09 | 14.45 | 14.17 | 14.75 |
Pivot Point | 13.71 | 13.71 | 13.84 | 13.70 | 13.71 |
Support 1 (S1) | 13.19 | 13.33 | 13.45 | 13.17 | 12.59 |
Support 2 (S2) | 12.71 | 13.09 | 12.70 | 12.50 | |
Support 3 (S3) | 12.19 | 12.71 | 12.42 | ||
Support 4 (S4) | 12.17 |